Trial Profile
Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetiks, and Pharmacodynamics of ILV-094 Administered Intravenously and One Dose of ILV-094 Administered Subcutaneously to Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 23 Jan 2008
Price :
$35
*
At a glance
- Drugs Fezakinumab (Primary) ; Fezakinumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- 12 Dec 2007 Status changed from in progress to completed.
- 09 Oct 2007 Status changed from recruiting to in progress.
- 07 May 2007 New trial record.